Home › New Data from IMPROVE-IT Study of VYTORIN (ezetimibe/simvastatin) and TRA 2P TIMI 50 Study of ZONTIVITY (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
 

Keywords :   


New Data from IMPROVE-IT Study of VYTORIN (ezetimibe/simvastatin) and TRA 2P TIMI 50 Study of ZONTIVITY (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

2015-02-25 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new data from two trials of the companys cardiovascular medicines will be presented at the 2015 American College of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San Diego. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of data american study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.04WasteNot Composts Liam Donnelly Dreams Big
29.04Delivery firm Getir to exit UK, Europe and US
29.04Recycling Works. If We Dont Counter the Naysayers, It Wont
29.04Kering Names New President and CEO
29.04Elina Organics Introduces Blemish-Fighting Roller
29.04Versed Skin Launches Third Hue in Mood Lighting Glow Drops
29.04Bread and biscuit prices could rise due to wet weather
29.04Columbia, Mo. Evaluates Options to Improve Recycling Facility
More »